Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Correction of intermittent hypoxia reduces inflammation in obese subjects with obstructive sleep apnea
Sebastio Perrini, … , Onofrio Resta, Francesco Giorgino
Sebastio Perrini, … , Onofrio Resta, Francesco Giorgino
Published September 7, 2017
Citation Information: JCI Insight. 2017;2(17):e94379. https://doi.org/10.1172/jci.insight.94379.
View: Text | PDF
Clinical Research and Public Health Metabolism Pulmonology

Correction of intermittent hypoxia reduces inflammation in obese subjects with obstructive sleep apnea

  • Text
  • PDF
Abstract

BACKGROUND. In obese subjects with obstructive sleep apnea (OSA), chronic intermittent hypoxia (CIH) may be linked to systemic and adipose tissue inflammation. METHODS. We obtained abdominal subcutaneous adipose tissue biopsies from OSA and non-OSA obese (BMI > 35) subjects at baseline and after 24 weeks (T1) of weight-loss intervention plus continuous positive airway pressure (c-PAP) or weight-loss intervention alone, respectively. OSA subjects were grouped according to good (therapeutic) or poor (subtherapeutic) adherence to c-PAP. RESULTS. At baseline, anthropometric and metabolic parameters, serum cytokines, and adipose tissue mRNA levels of obesity-associated chemokines and inflammatory markers were not different in OSA and non-OSA subjects. At T1, body weight was significantly reduced in all groups. Serum concentrations of IL-2, IL-4, IL-6, MCP-1, PDGFβ, and VEGFα were reduced by therapeutic c-PAP in OSA subjects and remained unaltered in non-OSA and subtherapeutic c-PAP groups. Similarly, adipose tissue mRNA levels of macrophage-specific (CD68, CD36) and ER stress (ATF4, CHOP, ERO-1) gene markers, as well as of IL-6, PDGFβ, and VEGFα, were decreased only in the therapeutic c-PAP group. CONCLUSION. CIH does not represent an additional factor increasing systemic and adipose tissue inflammation in morbid obesity. However, in subjects with OSA, an effective c-PAP therapy improves systemic and obesity-associated inflammatory markers. FUNDING. Ministero dell’Università e della Ricerca and Progetti di Rilevante Interesse Nazionale.

Authors

Sebastio Perrini, Angelo Cignarelli, Vitaliano Nicola Quaranta, Vito Antonio Falcone, Stella Kounaki, Stefania Porro, Alessandro Ciavarella, Romina Ficarella, Maria Barbaro, Valentina Annamaria Genchi, Pasquale Nigro, Pierluigi Carratù, Annalisa Natalicchio, Luigi Laviola, Onofrio Resta, Francesco Giorgino

×

Figure 4

Effects of intervention on circulating cytokines.

Options: View larger image (or click on image) Download as PowerPoint
Effects of intervention on circulating cytokines.
Serum levels of IL-2, ...
Serum levels of IL-2, IL-4, IL-6, IL-10, MCP-1, PDGFβ, VEGFα, and RANTES were assessed in non-OSA (white bars), OSA therapeutic c-PAP (black bars), and OSA subtherapeutic c-PAP (gray bars) subjects before and after 24 weeks of treatment, as indicated in Figure 1. Absolute serum levels (pg/ml) were determined by Bio-Plex assay, as described in the Methods. Results shown are mean ± SEM of changes versus baseline (n = 2 measurements for each subject; n = 15 non-OSA; n = 16 OSA therapeutic c-PAP; and n = 15 OSA subtherapeutic c-PAP). *P < 0.05 vs. baseline (1-sample t test); #P < 0.05 vs. non-OSA and OSA subtherapeutic c-PAP (1-way ANOVA). OSA, obstructive sleep apnea; c-PAP, continuous positive airway pressure.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts